Evidence map›Paper›PMID 42686780›Full record

ReviewNature communications2026

Multi-objective optimization in the context of generative chemistry.

Paula Torren-Peraire, Nadine Schneider, Raquel Rodríguez-Pérez, Robin A Fairhurst, Jessica Lanini

Abstract readReview
In one paragraph

Review in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paula Torren-PeraireBiomedical Research, Novartis Pharma AG, 4056, Basel, Switzerland. paula.torren_peraire@novartis.com.ORCID http://orcid.org/0000-0003-4390-4598
Nadine SchneiderBiomedical Research, Novartis Pharma AG, 4056, Basel, Switzerland. nadine-1.schneider@novartis.com.ORCID http://orcid.org/0000-0001-5824-2764
Raquel Rodríguez-PérezBiomedical Research, Novartis Pharma AG, 4056, Basel, Switzerland.ORCID http://orcid.org/0000-0002-2992-3402
Robin A FairhurstBiomedical Research, Novartis Pharma AG, 4056, Basel, Switzerland.ORCID http://orcid.org/0000-0002-9924-6291
Jessica LaniniBiomedical Research, Novartis Pharma AG, 4056, Basel, Switzerland.ORCID http://orcid.org/0009-0007-9194-008X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Designing new medicines requires balancing multiple competing objectives, including biological activity, pharmacokinetics and safety. As generative chemistry expands our ability to explore chemical space, the choice of how objectives are defined, combined and evaluated becomes increasingly important. In this Perspective, we discuss the role of multi-objective optimization in molecular generation, highlighting practical considerations, methodological challenges and emerging opportunities for translating these approaches into effective drug discovery tools.

Identifiers

PMID42686780
PMCPMC13538683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.